SCHEMBL928875

SCHEMBL928875

CC(=O)N(C)Cc1ccc(C)c(C#N)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
POLB P06746 3/20 0.36
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
GLA P06280 1/20 0.36
RCE1 Q9Y256 1/20 0.36
MAPT P10636 2/20 0.35
LMNA P02545 1/20 0.35
USP30 Q70CQ3 1/20 0.33
USP8 P40818 1/20 0.32
IKBKB O14920 1/20 0.32
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.31
XDH P47989 1/20 0.31
MCHR1 Q99705 1/20 0.31
NSD2 O96028 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2959006 0.75 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2KDM4EHPGDMAPT
SCHEMBL929492 0.74 CCR1 (0.42) ALDH1A1MAPTUSP8KMT2ACTSK
SCHEMBL28344631 0.72 HSD17B10 (0.38) ALDH1A1POLBGAASMN1; SMN2KDM4E
SCHEMBL25786895 0.71 MEN1 (0.37) ALDH1A1KDM4EMAPTLMNAUSP8
SCHEMBL2953123 0.71 ALDH1A1 (0.34) ALDH1A1SMN1; SMN2MAPTUSP8KMT2A
SCHEMBL6840494 0.70 RAB9A (0.43) ALDH1A1POLBSMN1; SMN2GLAMAPT
SCHEMBL13202515 0.69 ALDH1A1 (0.35) ALDH1A1GAASMN1; SMN2KDM4EMAPT
SCHEMBL21400321 0.68 CYP1A2 (0.53) SMN1; SMN2KDM4EKMT2A
SCHEMBL28341815 0.68 CCR1 (0.36) ALDH1A1
SCHEMBL16132153 0.67 RAB9A (0.40) ALDH1A1POLBSMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875600-B2 Pyrimidine compounds as purine receptor antagonist VERNALIS (R&D) LIMITED (GB) 2011-01-25 US disclosed
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide VERNALIS (R & D ) LIMITED (GB) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide ADORA2A, ADORA3, ADORA1 ALDH1A1 562/4885POLB 2730/4885GAA 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.